Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) price closed lower on Monday, May 06, dropping -1.58% below its previous close.
A look at the daily price movement shows that the last close reads $0.38. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.34 and 52-week low of $0.13. The stock subtracted -42.55% on its value in the past month.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give BCLI a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 50% Sell.
The overview shows that BCLI’s price is at present -29.06% off the SMA20 and -22.85% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 36.56, with weekly volatility standing at 31.97%. The indicator jumps to 19.61% when calculated based on the past 30 days. Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s beta value is holding at 0.36, while the average true range (ATR) indicator is currently reading 0.09.
An analysis of the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock in terms of its daily trading volume indicates that the 3-month average is 985.25K.
Current records show that the company has 60.49M in outstanding shares. The insiders’ percentage holdings are 18.91% of outstanding shares while the percentage share held by institutions stands at 6.06%. But the 37.00% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
